L
Lawrence Cher
Researcher at Austin Hospital
Publications - 56
Citations - 2204
Lawrence Cher is an academic researcher from Austin Hospital. The author has contributed to research in topics: Temozolomide & Population. The author has an hindex of 17, co-authored 52 publications receiving 1882 citations. Previous affiliations of Lawrence Cher include University of New South Wales & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor,Paul Mulholland,Bart Neyns,L. Burt Nabors,Mario Campone,Antje Wick,Warren P. Mason,Tom Mikkelsen,Surasak Phuphanich,Lynn S. Ashby,John DeGroot,Rao Gattamaneni,Lawrence Cher,Mark Rosenthal,F. Payer,Juliane M. Jürgensmeier,Rakesh K. Jain,A. Gregory Sorensen,John Xu,Qi Liu,Martin J. van den Bent +20 more
TL;DR: This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomUSTine in patients with recurrent glioblastoma, although cedIRanib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.
Journal ArticleDOI
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick,Vinay K. Puduvalli,Marc C. Chamberlain,Martin J. van den Bent,Antoine F. Carpentier,Lawrence Cher,Warren P. Mason,Michael Weller,Shengyan Hong,Luna Musib,Astra M. Liepa,Donald Thornton,Howard A. Fine +12 more
TL;DR: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.
Journal ArticleDOI
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A. Brandes,Antoine F. Carpentier,Santosh Kesari,Juan M. Sepúlveda-Sánchez,Helen Wheeler,Olivier Chinot,Lawrence Cher,Joachim P. Steinbach,David Capper,Pol Specenier,Jordi Rodon,Ann Cleverly,Claire Smith,Ivelina Gueorguieva,Colin Miles,Susan C. Guba,Durisala Desaiah,Michael Lahn,Wolfgang Wick +18 more
TL;DR: Galunisertib + lomustine failed to demonstrate improved OS relative to placebo + lmustine, and patients treated with galun isertib alone had fewer drug-related grade 3/4 adverse events compared with lomUSTine-treated patients.
Journal ArticleDOI
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field,John Simes,Anna K. Nowak,Lawrence Cher,Helen Wheeler,Elizabeth Hovey,Chris Brown,Elizabeth H Barnes,Kate Sawkins,Ann Livingstone,Ron Freilich,Pramit M. Phal,Gregory J Fitt,Cabaret,Cogno investigators,Mark Rosenthal +15 more
TL;DR: Adding carboplatin resulted in more toxicity without additional clinical benefit, and clinical outcomes in patients with recurrent GBM treated with bevacizumab were inferior to those in previously reported studies.
Journal ArticleDOI
Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.
TL;DR: Although combination therapy with rituximab and chemotherapy has been shown to be superior to chemotherapy alone in other forms of NHL, this does not appear to be the case in patients with NL, which may reflect the inability of ritUXimab to adequately penetrate into the central and peripheral nervous system.